Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epimedium Prenylflavonoids Extract
- Development stage
- Unknown
- Lead developer
- National University Hospital
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Epimedium Prenylflavonoids Extract is a standardized botanical extract derived from the *Epimedium* plant (Berberidaceae), developed by researchers at the National University Hospital, Singapore. It is being investigated as a pharmaceutical-quality intervention for postmenopausal osteoporosis and cardiovascular disease. The extract contains a complex of prenylflavonoid compounds, including icariin, icariside I, icariside II, icaritin, and desmethylicaritin. It functions as a selective estrogen receptor modulator (SERM), influencing bone remodeling by targeting estrogen receptors and markers such as bone-specific alkaline phosphatase (BSAP) and the osteoclast adaptor protein TRAF6. Additionally, the extract has demonstrated cardiovascular benefits through nitric oxide-dependent vasorelaxation and improvements in endothelial function. Clinical development has included Phase 1 trials in healthy men to establish safety and pharmacokinetics, as well as studies in postmenopausal women to evaluate bone health markers.
- Other names
- Standardized Epimedium Prenylflavonoids Extract
02
Targets
TRAF6ALPL (Tissue-nonspecific alkaline phosphatase)ESR1 (ERα)
Beyond the preview
Go deeper on Epimedium Prenylflavonoids Extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epimedium Prenylflavonoids Extract.